Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE: Becotatug Vedotin Plus Pucotenlimab in Advanced Refractory Solid Tumors
NCT07712029Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in solid tumor, sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07712029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712029.